Study to Assess the Efficacy and Safety of Somatostatin in the Treatment of Acute Severe Upper Gastrointestinal Bleeding

Inclusion Criteria: * Male or female non-cirrhotic patients at least 18 years old suspected to bleed from PU. * Patients with haematemesis and/or hematochezia and/or melena which have been observed by a member of a clinical team (GP, hospital physician, nurse, ...). * Either, documented signs of hypovolemia related to the current bleeding episode Or, occurrence of symptoms of hypovolemia Exclusion Criteria: * Treatment of the present bleeding episode with somatostatin or its analogues, vasoactive drugs, or endoscopic therapy. * Any treatment with PPIs (IV or per os) within the last 48 hours preceding randomisation. * Treatment (endotherapy or pharmacotherapy) for upper gastrointestinal ulcer bleeding in the last 30 days. * Deficient haemostasis (platelets \< 40 x 109/l, international normalised ratio of the prothrombin time \> 1.5 (or prothrombin time \< 70%), or activated partial thromboplastin time \> 40 seconds (or according to the normal ranges validated, from local lab)) * Anticoagulant therapy (vitamin K antagonists or heparin including LMW heparins) * Terminal stage illness in which endoscopy is contraindicated